Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

A Boehringer Ingelheim Pharma GmbH & Co. KG patent describes new phenylpiperidine derivatives acting as glutaminyl-peptide cyclotransferase (QPCT; QC) and glutaminyl-peptide cyclotransferase-like ...

Surrozen Inc. has announced that Boehringer Ingelheim Pharma GmbH & Co. KG will further develop SZN-413 to advance the compound and prepare it for clinical testing. Boehringer decided to move forward ...

INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal ...

AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...

As our digital focus continues, Daniel Ghinn explores the growing anticipation around Boehringer Ingelheim’s launch of Syrum – the first pharmaceutical social game – ahead of its beta launch ...

Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth ...

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment ...